Tylerdipine hydrochloride is a novel L-type and T-type dual calcium channel antagonist that has the potential effects of expanding blood vessels and lowering blood pressure. It is expected to reduce the side effect of ankle edema observed with other drugs in the same class. A randomized, open-label, crossover phase 1 study was performed to evaluate the effect of food on the bioavailability of tylerdipine. Fourteen healthy male volunteers were enrolled. The administration of tylerdipine after a high-fat meal increased the bioavailability of tylerdipine. In the fed state there was a 130% increase in the mean total systemic exposure (AUC inf ) and a 73% increase in the mean peak plasma concentration (C max ) compared with that in the fasting state. The geometric mean ratios (90% confidence interval) of C max and AUC inf were 2.54 (1.94, 3.33) and 1.75 (1.50, 2.04) for tylerdipine. The exposures of the 2 main metabolites M2 and M4 were increased by approximately 10% after a high-fat meal. The median time to peak plasma concentration of tylerdipine showed no difference between fasting and fed states.
Hypertension is one of the most prevalent cardiovascular diseases and is also the main cause of stroke. According to the World Health Organization and Medscape reports in 2016, the overall prevalence of elevated blood pressure in adults aged 25 and over was approximately 40% in 2008 globally. The number of hypertensive adults worldwide was estimated to be 1.1 billion in 2015. 1 It has been estimated that 1.56 billion people will have hypertension by the year 2025. 2 In 1883 Sidney Ringer reported the importance of calcium in muscle contraction. 3 In the 1960sthe mechanism of the calcium channel blockers was discovered 4 ; subsequently, several calcium channel blockers, such as nifedipine, amlodipine, and other dihydropyridines, have been developed and approved for the treatment of hypertension. [5] [6] [7] [8] These calcium channel blockers were shown to be slightly more effective than β-blockers at lowering cardiovascular mortality, but they are also associated with some other side effects such as tachycardia, coprostasis, and ankle edema. [9] [10] [11] [12] [13] [14] [15] [16] [17] Tylerdipine hydrochloride is a novel L-type and T-type dual calcium channel antagonist that has potential effects of expanding blood vessels and lowering blood pressure. In the preclinical studies tylerdipine was demonstrated to have a similar effect as amlodipine on lowering the blood pressure in spontaneously hypertensive rats and in dogs with renal hypertension; meanwhile, the heart rate was found to decrease in the groups administered tylerdipine. In the deoxycorticosterone acetate-and salt-induced renal injury model, it was found that the heart rate, the urinary albumin, and the cardiac index decreased in the rats dosed with tylerdipine compared with the placebo group (unpublished data). Thus, tylerdipine is expected to reduce the side effects of tachycardia and ankle edema that are observed with other drugs in the same class.
A phase 1 single-ascending-dose study was designed to evaluate the safety and pharmacokinetics of tylerdipine. Fifty-two healthy Chinese male volunteers were randomized into 5 dose-level groups (5, 10, 20, 25 , and 30 mg) and administered oral tylerdipine tablets. It was found that tylerdipine was well tolerated in single doses up to 30 mg in the fasting state. The median time to peak plasma concentration (T max ) ranged from 1 to 3 hours, and the elimination half-life (t 1/2 ) ranged from 18 to 21 hours. The maximum concentration following administration (C max ) was 0.9993 to 10.31 ng/mL, and the area under the curve of plasma concentration in 72 hours (AUC 0-72h ) was 4.332 to 73.95 h·ng/mL. AUC and C max increased faster than the dose escalation in the 5-to 30-mg dose range. The 120-hour fecal cumulative excretion rate of the parent drug was 2.19% after a single oral dose of 20 mg of tylerdidpine in healthy Chinese subjects, and little tylerdipine was recovered in human urine.
Two main metabolites, M2 and M4 (structures shown in Figure 1 ), were identified in the previous trials, with exposures of 30-fold and 17-fold (adjusted with the molecular weights) of the parent compound, respectively. The concentration of the inhibitor where the response is reduced by half (IC50) of the parent drug on the L-type calcium channel in vitro was 0.91 μmol/L, whereas the IC50 of M4 was much higher than 10 μmol/L. An experiment was performed to evaluate the activity of M4 in the spontaneously hypertensive rat under the same exposure of M4 when tylerdipine was administered at its effective dose. The results showed that M4 had no effect on lowering the blood pressure at that exposure. M2 is the common metabolite of the other drugs in the same class. It was reported that M2 had no activity or toxicity. 18 The elimination half-lives of M2 and M4 were 7.78 to 13.15 hours and 2.77 to 5.71 hours, respectively. It was found that cytochrome P450 (CYP)3A played the key role in the biotransformation of tylerdipine in human liver microsomes. CYP3A4*1G and CYP3A5*3 polymorphisms may influence tylerdipine pharmacokinetics in healthy Chinese subjects. 19 Food can potentially alter the bioavailability by decreasing, delaying, or accelerating absorption and metabolism, which may result in unpredictable clinical effects. 20, 21 Therefore, to optimize the timing of administration in relation to meals, it is necessary to investigate the effect of food on the bioavailability of tylerdipine. According to the IC50 in vitro and the exposure observed in the single-dose study, the clinical dose was expected to be 10 to 20 mg; therefore, 15 mg was chosen to be the administered dose in the food effect study.
Methods Subjects
The study protocol and protocol amendments were approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University and conducted in compliance with the ethical principles set forth in the Declaration of Helsinki (1989) as well as the Principles of Good Clinical Practice. This study was registered at the China Food and Drug Administration (No. CTR20150658) and conducted in the Phase 1 Clinical Trial Unit of the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). All subjects provided written informed consent before participating in the study.
Fourteen healthy male adults aged 18 to 45 years were eligible for study participation. There was a requirement for a minimum body weight of 50.0 kg, with a body mass index of 19.0 to 25.0 kg/m 2 . All subjects were required to present clinically normal physical findings and laboratory values. Exclusion criteria for this study included a history of psychiatric or somatic illness; a history of severe allergy/hypersensitivity; systolic pressure of 95 mm Hg or less or diastolic pressure of 65 mm Hg or less; intake of any prescribed medicine or herbal supplements within 2 weeks before the initial dosing; intake of any over-the-counter medication or vitamins within 1 week before the initial dosing; participation in any clinical investigation within 3 months before the initial dosing; blood donation or blood loss of 400 mL or more within 3 months before the initial dosing; past or present alcohol or drug abuse; and use of nicotine-containing substances during study.
Study Design
This was a randomized, open-label, 2-period crossover study conducted in healthy adult subjects. The objective of the study was to evaluate the effect of a high-fat meal on the bioavailability of a 15-mg single dose of tylerdipine compared with the fasting state. After eligibility confirmation during the screening period, subjects were randomly assigned to 2 groups (A and B) with a 1:1 ratio. The subjects were confined to the study site for at least 12 hours before the treatment was started. In period 1, after an overnight 10-hour fast, the subjects in group A received a single 15-mg oral dose of tylerdipine under the fasting condition, whereas the subjects in group B received a 15-mg single oral dose of tylerdipine at 30 minutes after a Food and Drug Administration standard high-fat breakfast meal (800-1000 kcal, 50% fat by calories). The treatment was administered with 250 mL of water. No other water was allowed within 2 hours after dosing, and no other food was allowed until 4 hours after dosing. All subjects were confined to the study site until 120 hours after dosing. After a 7-day washout phase, the subjects were crossed over to the other treatment.
Pharmacokinetic Analysis
Blood samples were collected at the following time points: predose; at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12, 24, 48, 72, 96, and 120 hours postdose. K 2 -ethylenediamine tetraacetic acid was used as an anticoagulant. Blood samples were centrifuged at 4000 rpm under 4°C for 5 minutes to obtain plasma samples. Plasma concentrations of tylerdipine and the metabolites were analyzed using a high-performance liquid chromatography-mass spectrometry method. The chromatographic separation was performed on an Agilent Poroshell 120 column (50 × 2.1 mm, 2.7 μm) under isocratic elution at a flow rate of 0. 
Statistical Analysis
The analysis of variance model was used to analyze the log-transformed AUCs and C max , with treatment as the main factor. The geometric mean ratios (GMR) with 90% confidence intervals (CIs) were obtained by backtransforming the estimated treatment differences (between the fed and fasting) and their CIs to the original scale.
Safety
Adverse events, physical examination findings, vital sign measurements, electrocardiograph readings, and clinical laboratory data were reviewed and summarized to evaluate the safety profile of tylerdipine in healthy subjects.
Results

Subject Demographics
Fourteen healthy male subjects were enrolled in the study, with equal numbers of subjects in the A and B groups (n = 7 each). All 14 subjects were included in the safety evaluation and the pharmacokinetic analysis. All the subjects were Chinese, with a mean ± SD age of 25.1 ± 3.3 years. The summary of demographics for all the subjects is listed in Table 1 .
Pharmacokinetics
The pharmacokinetic parameters of tylerdipine, M2, and M4 following a 15-mg single-dose administration with or without a high-fat meal are summarized in Table 2 . The concentration-time profiles were shown in Figure 2 .
Compared with the fasting state, the mean C max increased by 130%, and the mean AUC inf increased by 73%, in the fed state, respectively. The GMRs (90%CI) of C max and AUC inf were 2.54 (1.94, 3.33) and 1.75 (1.50, 2.04) for tylerdipine, indicating that food can significantly increase the exposure of tylerdipine.
Following an intensive investigation on the individual exposures with and without a meal, it was found that the exposures in the fed state increased by a minimum 0.13-fold and a maximum 2.3-fold compared with that in the fasting state (Figure 3 ), suggesting that there might be an interindividual variation in the increase of exposure under the fed condition. No delay of T max and no significant difference of t 1/2 were observed in the fed state compared to in the fasting state. The GMRs and associated 90%CI values of C max and AUC inf for M2 and M4 demonstrated that the exposures of the 2 main metabolites M2 and M4 were slightly increased after a high-fat meal. No delay of T max and no significant difference of t 1/2 were observed in the fed state compared with in the fasting state.
Safety
All 14 subjects were included in the assessment of safety and tolerability. No drug-related adverse event was observed in this study.
Discussion
In the present study we found that the mean C max and the mean AUC inf of tylerdipine increased by approximately 130% and 73%, respectively, when the drug was administered with food rather than under fasting conditions in healthy Chinese male subjects. No significant differences for T max or t 1/2 were observed between the fed and fasting conditions.
Because the food effect estimated in the present study is based on a high-fat meal, it is likely to represent a worst-case extreme of the potential food effect in subjects for whom tylerdipine is indicated because lighter meals are more typical. Thus, the effect of lighter (ie, lower-fat) meals on tylerdipine exposure after administration may be less than the increase observed in the current study.
In the previous clinical studies tylerdipine was shown to be well tolerated in single doses up to 30 mg. The mean exposure (AUC inf ) was 83.6 ± 41.8 h·ng/mL (maximum 126.3 h·ng/mL) in the subjects administered with 30 mg of tylerdipine in the fasting state. In the current study the mean exposure (AUC inf ) in subjects administered a single dose of 15 mg of tylerdipine under fed conditions was 69.7 ± 20.6 h·ng/mL (maximum 102.5 h·ng/mL), less than the exposure of a single dose of 30 mg. However, the therapeutic dose had not been determined, and the safety of multiple doses was unknown; thus, there was insufficient evidence to determine whether the tylerdipine tablets could be taken with a meal. The final therapeutic dose range and the tolerance in multiple-dose studies should be taken into consideration. There were 2 main metabolites with exposures that were severalfold greater than the exposures of the parent drug. We calculated the percentage of the metabolite exposures compared with the parent exposure and found that the AUC inf,M2 /AUC inf,parent were 26.4 and 15.8 in the fasting and fed states, respectively; the AUC inf,M4 /AUC inf,parent were 14.8 and 9.3 in the fasting and fed states, respectively. We referred to the percentages obtained in the single-dose study that was conducted under the fasting condition. The AUC inf,M2 /AUC inf,parent was approximately 30.0, and the AUC inf,M4 /AUC inf,parent was approximately 17.4, which were similar to the results in the present study. All the ratios had been adjusted with the molecular weights. The results showed that the exposure of the parent drug increased with food, but the ratios of the metabolite exposures versus the parent exposure decreased.
The exposure of the parent drug increased significantly, and the exposures of M2 and M4 increased slightly in the fed state, suggesting that the total drugrelated exposure increased. Because the 2 metabolites were found mainly in urine and only slightly in feces, and the T max was approximately 2 to 3 hours, consistent with the parent drug (unpublished data of singledose study), it seemed that M2 and M4 might not be the products of the intestinal flora and more likely were the products of the intestinal or hepatic enzymes. Thus, there might be an increase of absorption.
Tylerdipine is a BCS class II drug with poor solubility and high permeability. We did not acquire the experimental solubility data in pH range or in simulation gastric fluids. However, we used the ADMET predictor (Version 9.0; Simulations Plus, Inc, Lancaster, California), a module of GastroPlus, which is physiologically based pharmacokinetic software, to estimate the solubility of tylerdipine. As shown in Figure S1 , the solubility reaches the maximum of 3.9 mg/mL at pH 1.6 and sharply decreases as the pH increases. Because food may elevate the gastric pH from 1.5 to 2 in the fasting state to approximately 5 in the fed state, 20, 21 these predicted data indicated that the increase of exposure in the fed state might not be due to the change of solubility in the stomach. On the other hand, this figure also indicated that the solubility of tylerdipine in water is very low in the small intestine because the pH of the small intestine is approximately 6 to 8. 20, 21 As we know, food may increase the secretion of bile salts, which may increase the absorption of some poorly soluble lipophilic drugs; thus, it is likely that a high-fat meal evoked an increase in bile salt secretion, enhancing the solubility of tylerdipine in the small intestine and increasing its bioavailability. Although the absorption of tylerdipine was increased after a high-fat meal, the metabolism seemed to be decreased, as the percentage of metabolite exposures compared to parent exposure in the fed state was less than that in the fasting state. We focused on the intestinal and hepatic metabolism. The factors that affect the metabolism were the blood flow, the free drug fraction, and the intrinsic clearance. In the fed state the gastrointestinal blood flow is thought to be increased; thus, this cannot explain the decrease in the metabolism. The free drug fraction might be changed after a high-fat meal, but we did not have any data to support that. The intrinsic clearance might be changed too because the food might compete with the drug for binding the metabolic enzymes; this might cause the decrease of the metabolism after a high-fat meal.
In conclusion, the increase of the exposure of tylerdipine might be a dual result of the increase of absorption and the decrease of metabolism. The variations in bile secretion and the intrinsic clearance in the fed state might be different among individuals, which may explain why the exposures increased differently among subjects. In addition, we analyzed tylerdipine, M2, and M4 in human urine and feces after a single dose of 20 mg. The total recovery was 14.8% in 0-120 hours after dosing, suggesting that there may be other metabolites to be identified, and the biotransformation pathways have not been studied clearly. Thus, further studies are required to help understand the pharmacokinetic behavior of this drug in humans.
Conclusions
The results of the study indicated that there was a significant effect of food on the pharmacokinetic parameters of tylerdipine. The AUC inf of tylerdipine increased by approximately 73%, and the C max increased by 130%, when the drug was administered with a high-fat meal compared with that under fasting conditions in healthy Chinese subjects. The T max of tylerdipine showed no differences between the fasting and fed states. No significant increase was observed for the AUC of the metabolites M2 and M4. The final therapeutic dose range and the tolerance in a multiple-dose study would be taken into consideration to determine whether the tylerdipine tablets could be taken with a meal.
